Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/07/2013US20130296379 Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid
11/07/2013US20130296378 Triazole compounds that modulate hsp90 activity
11/07/2013US20130296377 Complement pathway modulators and uses thereof
11/07/2013US20130296368 Sublingual fentanyl spray
11/07/2013US20130296367 Compositions and methods for alleviating depression or improving cognition
11/07/2013US20130296366 Optical isomers of an iloperidone metabolite
11/07/2013US20130296365 Quinoline derivative-containing pharmaceutical composition
11/07/2013US20130296364 Modulators of atp-binding cassette-transporters
11/07/2013US20130296363 Quinoline and isoquinoline derivatives for use as jak modulators
11/07/2013US20130296362 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
11/07/2013US20130296359 Treatment of solid tumors with rapamycin derivatives
11/07/2013US20130296356 Combinations
11/07/2013US20130296351 2-Thiopyrimidinones
11/07/2013US20130296347 Compositions and Methods for Prophylaxis and Treatment of Addictions
11/07/2013US20130296345 Methods for treating hyperuricemia and related diseases
11/07/2013US20130296342 Lipoprotein lipase-activating compositions comprising benzene derivates
11/07/2013US20130296337 Flashmelt oral dosage formulation
11/07/2013US20130296336 5-ht1a receptor subtype agonist
11/07/2013US20130296331 Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
11/07/2013US20130296330 Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
11/07/2013US20130296327 Substituted heterocylic compounds
11/07/2013US20130296326 Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
11/07/2013US20130296325 HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
11/07/2013US20130296324 Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
11/07/2013US20130296322 Serotonin reuptake inhibitors
11/07/2013US20130296318 Compounds and compositions as protein kinase inhibitors
11/07/2013US20130296316 Antiparasitic Agents Based On mTOR Inhibitors
11/07/2013US20130296314 Gastric and colonic formulations and methods for making and using them
11/07/2013US20130296309 Aryl pyridine as aldosterone synthase inhibitors
11/07/2013US20130296305 Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
11/07/2013US20130296303 Spiro-oxindole mdm2 antagonists
11/07/2013US20130296300 Quinolines and aza-quinolines as crth2 receptor modulators
11/07/2013US20130296295 Bcl-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases
11/07/2013US20130296294 Treatment and/or prevention of parkinson's disease dementia with ceftriaxone
11/07/2013US20130296293 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
11/07/2013US20130296292 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
11/07/2013US20130296291 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
11/07/2013US20130296290 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
11/07/2013US20130296289 Anti-dandruff shampoo
11/07/2013US20130296287 Focal photodynamic therapy methods
11/07/2013US20130296286 Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
11/07/2013US20130296282 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis
11/07/2013US20130296277 Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration
11/07/2013US20130296275 Oxazolidinone-quinolone hybrid antibiotics
11/07/2013US20130296274 Pyrrolidinones as metap-2 inhibitors
11/07/2013US20130296273 Treatment of blood cancer
11/07/2013US20130296266 Pharmaceutical Composition of Complex Carbohydrates and Essential Oils and Methods of Using the Same
11/07/2013US20130296265 Methods of Skin Treatment and Use of Water-Soluble Beta-(1,3) Glucans as Active Agents for Producing Therapeutic Skin Treatment Agents
11/07/2013US20130296264 Ophthalmic compositions with improved dessication protection and retention
11/07/2013US20130296263 Hyaluronic acid stabilizer
11/07/2013US20130296262 Hyaluronic acid stabilizer
11/07/2013US20130296261 Cancer Treatment Method
11/07/2013US20130296253 Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum
11/07/2013US20130296237 Use Of Chloroquine To Treat Metabolic Syndrome
11/07/2013US20130296236 Treatment protocol of diabetes type 2
11/07/2013US20130296230 Method for treating malaria, method for killing malaria parasite, and use of the methods
11/07/2013US20130296228 Efflux pump inhibitors
11/07/2013US20130296227 Antimicrobial cationic peptides and formulations thereof
11/07/2013US20130296179 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
11/07/2013US20130295615 Method for expression of small antiviral rna molecules with reduced cytotoxicity within a cell
11/07/2013US20130295204 Formulations comprising saponins and uses thereof
11/07/2013US20130295203 Methods and compositions for the treatment of neuropsychiatric disorders
11/07/2013US20130295202 Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
11/07/2013US20130295201 Methods for Inhibiting Sensory Nerves by Topically Administering Strontium-Containing Compositions to Keratinized Skin
11/07/2013US20130295199 Composition Comprising OPC and Omega-3 for Preventing and/or Inhibiting the Development of Diabetic Retinopathy
11/07/2013US20130295196 Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof
11/07/2013US20130295187 NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
11/07/2013US20130295185 Compounds and methods for inducing apoptosis in cancer cells using a bh3 alpha-helical mimetic
11/07/2013US20130295183 Stable Formulations for Lyophilizing Therapeutic Particles
11/07/2013US20130295182 Liquid crystalline phytosterol-glycerine complex for enhanced bioavailability and water dispersal
11/07/2013US20130295179 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
11/07/2013US20130295178 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
11/07/2013US20130295177 Controlled release hydrocodone
11/07/2013US20130295175 Orally disintegrating tablet
11/07/2013US20130295174 Tablet comprising a first and second region
11/07/2013US20130295173 Compositions of statins and omega-3 fatty acids
11/07/2013US20130295172 Medical compositions, methods of making and using those compositions, and kits including those compositions
11/07/2013US20130295171 Krill oil and reacted astaxanthin composition and associated method
11/07/2013US20130295169 Pharmaceutical Compositions Containing Dimethyl Fumarate
11/07/2013US20130295168 Oral Drug Delivery System
11/07/2013US20130295166 Testosterone formulations
11/07/2013US20130295159 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
11/07/2013US20130295158 Composition for the transdermal delivery of fentanyl
11/07/2013US20130295151 Process for the treatment of cellulosic molded bodies
11/07/2013US20130295146 Composition for Improving Membrane Composition and Functioning of Cells
11/07/2013US20130295145 Topical pharmaceutical compositions comprising etodolac
11/07/2013US20130295142 Immunotherapy using allo-nkt cells, cells for immunotherapy in which alpha chain of t-cell receptor (tcr) gene has been rearranged to uniform v-alpha-j-alpha, and banking of nkt cells derived from said cells
11/07/2013US20130295141 Matrix metalloproteinase inhibitors
11/07/2013US20130295130 Composition for promoting lipolysis
11/07/2013US20130295117 Aldosterone induced elastin production
11/07/2013US20130295115 Compositions and methods for treating alphavirus infection
11/07/2013US20130295111 Methods and compositions for treating disorders associated with hyperactive immune system
11/07/2013US20130295083 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
11/07/2013US20130295082 Antibody formulations and methods
11/07/2013US20130295078 Method of improving absorption of vitamin e by a pet animal
11/07/2013US20130295075 Compositions and methods of treating glaucoma
11/07/2013US20130295074 Pyridoxamine for the Treatment of Diabetic Kidney Disease
11/07/2013US20130295073 Use of pegylated recombinant human arginase for treatment of leukemia
11/07/2013US20130295068 Combination preparation for improving sperm quality
11/07/2013US20130295051 Novel compounds and compositions for the inhibition of nampt
1 ... 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 ... 7860